3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Advanced Cancer
4
Melanoma
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Gastric Cancer
1
Interventions
Gemcitabine
47
Cisplatin
32
pembrolizumab
28
Paclitaxel
13
Docetaxel
13
avelumab
12
Mitomycin
12
atezolizumab
11
Nivolumab
11
Cystectomy
10
Carboplatin
9
durvalumab
7
Sunitinib
7
apaziquone
6
Doxorubicin
6
BCG Vaccine
6
5-aminolevulinic acid hexyl ester
6
Vinblastine
5
Radiation
5
Platinum
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
Taxes
4
Standard of Care
4
Sorafenib
4
Radiotherapy
4
Fluorouracil
4
Erlotinib Hydrochloride
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urinary Bladder Neoplasms
×
linrodostat
×
Clear all
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts